Clinical trials are designed to add to medical knowledge and most importantly, the results of these trials can make a difference in the care and treatment of Sjögren’s patients. A clinical trial is important because it contributes to the advancement of science. It provides the participants an opportunity to receive potential benefit from a drug, medical device or procedure or even a lifestyle change such as diet or exercise. The Sjögren’s Foundation is fully committed to the development of new therapeutics that will treat the entire disease, not just one symptom.
Click here to stay up to date on clinical trial and patient recruitment.
The items on this page provide you with:
- Information about participating in clinical trials, including a video
- A State-by-State listing of actively enrolling clinical trials from corporations providing support to the Sjögren’s Foundation
- Other websites listing clinical trials, including easy instruction to navigate the clinicaltrials.gov site.
The following links will provide you with additional knowledge about clinical trials, what's involved and what to expect:
Watch this presentation from our 2022 National Patient Conference. Clinical Trials: What Every Patient Should Know presented by Dr. Herbert Baraf (Accompanying Slides)
- All About Clinical Trials and Sjögren’s
- What to know about Clinical Trials and Sjögren’s
- Clinical Trials 101 (PDF - 106 KB)
- Clinical Trials: Getting Involved (PDF - 104 KB
Below is a listing of active Sjögren’s Clinical trials from companies supporting the Foundation’s mission. These listings are enrolling patients:
This is not an all inclusive list - for additional trials please use the links at the bottom of the page.
Chandler
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Amer Al-Khoudari, MD
Arizona Research Clinic PLLC
604 W Warner Rd Ste C3
Chandler, AZ 85225-2915
Contact: Divya Chauhan
Phone: (480) 556-1359
Email: divya [dot] chauhan [at] azarthritis [dot] com (divya[dot]chauhan[at]azarthritis[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Amer Al-Khoudari, MD, FACR
Arizona Research Clinic PLLC
4550 E Bell Road, Building 8, Ste 272
Phoenix, AZ 85032
Contact: Francesca Ingram
Phone: (602) 368-9667
Email: francesca [dot] ingram [at] azarthritis [dot] com (francesca[dot]ingram[at]azarthritis[dot]com)
Flagstaff
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Alexander Hu, DO
Arizona Arthritis and Rheumatology Associates - Flagstaff
399 S Malpais Ln Ste 108
Flagstaff, AZ 86001-6299
Contact: Thomas Huck
Phone: (480) 350-7655
Email: thomas [dot] huck [at] azarthritis [dot] com (thomas[dot]huck[at]azarthritis[dot]com)
Gilbert
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Daniel Kreutz, MD
Arizona Arthritis and Rheumatology Associates - Gilbert
3645 S Rome St Ste 201
Gilbert, AZ 85297-7338
Contact: Lynea Klemmedson
Phone: (480) 443-8400
Email: lynea [dot] klemmedson [at] azarthritis [dot] com (lynea[dot]klemmedson[at]azarthritis[dot]com)
Glendale
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Saima Chohan, MD
Arizona Arthritis and Rheumatology Associates - Glendale
5681 W Beverly Ln Ste 100
Glendale, AZ 85306-9800
Contact: Revathi Pillai
Phone: (480) 626-6650
Email: revathi [dot] pillai [at] azarthritis [dot] com (revathi[dot]pillai[at]azarthritis[dot]com)
Mesa
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Areena Swarup, MD
Arizona Arthritis and Rheumatology Research- Mesa
2152 S. Vineyard Ave. Suite 129
Mesa, Arizona 85210
Contact: Francesca Ingram
Phone: (480) 321-8581
Email: francesca [dot] ingram [at] azarthritis [dot] com (francesca[dot]ingram[at]azarthritis[dot]com)
Phoenix
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Matthew Herrmann, MD
Arizona Arthritis and Rheumatology Associates - Paradise Valley
4550 E. Bell Rd. Suite 170
Phoenix, Arizona 85032
Contact: Ramya Rameshkumar
Phone: (480) 626-6657
Email: ramya [dot] rameshkumar [at] azarthritis [dot] com (ramya[dot]rameshkumar[at]azarthritis[dot]com)
Tucson
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Jeffrey Loomer MD
Arizona Arthritis and Rheumatology Associates - Tucson
2001 W Orange Grove Rd Ste 104
Tucson, AZ 85704-1140
Contact: Rishika Bysani
Phone: (520) 332-2952
Email: rishika [dot] bysani [at] azarthritis [dot] com (rishika[dot]bysani[at]azarthritis[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Jeffrey Loomer MD
Arizona Arthritis and Rheumatology Associates - Tucson
2001 W Orange Grove Rd Ste 104
Tucson, AZ 85704-1140
Contact: Laronda Lee
Phone: (480) 443-8400
Email: laronda [dot] lee [at] azarthritis [dot] com (laronda[dot]lee[at]azarthritis[dot]com)
Beverly Hills
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Daniel Wallace, MD
Wallace Rheumatic Studies Center, LLC
8750 Wilshire Blvd Ste 210
Beverly Hills, CA 90211-2703
Contact: Erin Avila
Phone: (310) 652-0920
Email: erin [at] walleemed [dot] com (erin[at]walleemed[dot]com)
Covina
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Samy Metyas, MD
Samy Metyas MD, Inc.
500 W. San Bernardino Ave. Ste. A
Covina, CA 91723
Contact: Victoria Torres
Phone: (562) 758-6600
Email: victoria [at] medvinresearch [dot] com (victoria[at]medvinresearch[dot]com)
Fullerton
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Shirley Pang
Providence Medical Foundation
2141 N Harbor Blvd
Fullerton, CA 92835
Contact: Angela Gonzalez
Phone: +1 714 446 5177
Email: angela [dot] gonzalez3 [at] providence [dot] org (angela[dot]gonzalez3[at]providence[dot]org)
La Jolla
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Monica Guma Uriel, MD
UCSD Altman Clinical and Translational Research Institute Building
9452 Medical Center Drive
La Jolla, CA 92093
Contact: Bosco Trinh
Phone: (858) 246-2387
Email: botrinh [at] health [dot] ucsd [dot] edu (botrinh[at]health[dot]ucsd[dot]edu)
Napa
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Eric Grigsby, MBA, MD
Neurovations
3444 Valle Verde Dr
Napa, California 94558-2415
Contact: Hilary Cromwell
Phone: (707) 252-9660
Email: hilary [at] neurovations [dot] com (hilary[at]neurovations[dot]com)
Santa Monica
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Orrin Troum
Providence Saint John s Health Center
2336 Santa Monica Blvd
Santa Monica, CA 90404
Contact: Amor Balki
Phone: +1 310 449 1999
Email: amro [dot] balki [at] providence [dot] org (amro[dot]balki[at]providence[dot]org)
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Orrin Troum, MD
Providence St. John's Health Center
2336 Santa Monica Blvd Ste 207
Santa Monica, CA 90404
Contact: Donna Cruz
Phone: (310) 449-1999
Email: donna [dot] cruz [at] providence [dot] org
San Francisco
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
John Gonzales, MD
UCSF- University of California San Francisco
513 Parnassus Avenue
San Francisco, CA 94143
Contact: Francisco Quintanilla Mejia
Email: francisco [dot] quintanilla [at] ucsf [dot] edu (francisco[dot]quintanilla[at]ucsf[dot]edu)
Upland
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Eric Lee
Inland Rheumatology Clinical Trials Inc.
1238 East Arrow Hwy
Upland, CA 91786
Contact: Daniel Dominguez
Phone: +1 909 982 0099
Email: ddominguez [at] irclinicaltrials [dot] com (ddominguez[at]irclinicaltrials[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Eric Lee, MD
Inland Rheumatology Clinical Trials Incorporated
1238 East Arrow Highway
Upland, CA 91786
Contact: Carlos Alvarez
Phone: (909) 296-8700
Email: calvarez [at] irclinicaltrials [dot] com (calvarez[at]irclinicaltrials[dot]com)
Denver
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Christopher Antolini, MD
Denver Arthritis Clinic
7111 East Lowry Blvd., Suite 200
Denver, CO 80230
Contact: Theresa Hernandez
Phone: (303) 394-2828
Email: thernandez [at] dacdenver [dot] com (thernandez[at]dacdenver[dot]com)
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Christopher Antolini, MD
Denver Arthritis Clinic
200 Spruce Street Suite 100
Denver, CO 80230
Contact: Theresa Hernandez
Phone: (303) 394-2828
Email: thernandez [at] dacdenver [dot] com (thernandez[at]dacdenver[dot]com)
Fort Collins
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Michael Thakor, MD
Tekton Research, LLC - Fort Collins - PPDS
2121 E Harmony Rd Unit 360
Fort Collins, CO 80528-3404
Contact: Tamra Meurer
Phone: (970) 267-9799
Email: tamra [dot] meurer [at] tektonresearch [dot] com (tamra[dot]meurer[at]tektonresearch[dot]com)
Bradenton
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Eric Folkens, MD
Bradenton Research Center Inc
3924 9th Ave W
Bradenton, FL 34205-1704
Contact: Gloria Carlbert
Phone: (941) 708-0005
Email: gloriacarlbert [at] bradentonresearch [dot] com (gloriacarlbert[at]bradentonresearch[dot]com)
Clearwater
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Robert Levin
Clinical Research of West Florida Inc
2147 Northeast Coachman Road
Clearwater, FL 33765
Contact: Sydney Mullen
Phone: +1 727 466 0078
Email: smullen [at] crwf [dot] com (smullen[at]crwf[dot]com)
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Robert Levin, MD
Clinical Research of West Florida
2147 NE Coachman Road
Clearwater, FL 33765
Contact: Maartje Brucculeri
Phone: (727) 466-0078
Email: mbrucculeri [at] crwf [dot] com (mbrucculeri[at]crwf[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Robert Levin, MD
Clinical Research of West Florida - Clearwater
2147 NE Coachman Road
Clearwater, FL 33765-2616
Contact: Jessica Mayfield
Phone: (727) 466-0078
Email: jmayfield [at] crwf [dot] com (jmayfield[at]crwf[dot]com)
Jacksonville
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Gurjit Kaeley
UF Health Rheumatology
10475 Centurion Parkway
Jacksonville, FL 32256
Contact: Caroline Howard
Phone: +1 904 633 0914
Email: caroline [dot] howard [at] jax [dot] ufl [dot] edu (caroline[dot]howard[at]jax[dot]ufl[dot]edu)
Miami
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Damian Casadesus, MD, PhD
Life Arc Research
860 NW 42nd Ave Suite 302
Miami, Florida 33126
Contact: Deybis Padron
Phone: (305) 874-7401
Email: dpadron [at] lifearcresearch [dot] health (dpadron[at]lifearcresearch[dot]health)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Eric Greidinger, MD
University of Miami- Leonard M. Miller School of Medicine
Don Soffer Clinical Research Building, Rm 1136
1120 NW 14th St.
Miami, FL 33136
Contact: Michael Mijares
Phone: (305) 243-6405
Email: mmijares74 [at] med [dot] miami [dot] edu (mmijares74[at]med[dot]miami[dot]edu)
New Port Richey
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Farrukh Zaidi
Suncoast Clinical Research
5604 Gulf Drive
New Port Richey, FL 34652
Contact: Melissa Hicks
Phone: +1 813 264 2155
Email: mhicks [at] suncoastclinicalresearch [dot] com (mhicks[at]suncoastclinicalresearch[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Cathy Barnes, MD
Suncoast Clinical Research
5604 Gulf Dr
New Port Richey, FL 34652-4020
Contact: Shonte Jones, LPN
Phone: (727) 789-2784 x23
Email: sjones [at] suncoastclinicalresearch [dot] com (sjones[at]suncoastclinicalresearch[dot]com)
Ormond Beach
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Michael Kohen, MD
Millennium Research
1545 Hand Ave Ste B2
Ormond Beach, Florida 32174-1140
Contact: Anastasiia Simpson-Adamova
Phone: (386) 672-1985
Email: anamillenium1 [at] gmail [dot] com (anamillenium1[at]gmail[dot]com)
Plantation
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Guillermo Valenzuela, MD
IRIS Research and Development LLC
140 SW 84th Ave Ste B
Plantation, Florida 33324-2736
Contact: Jhon Galindo
Phone: (954) 476-2338 x109
Email: jgalindo [at] irisrheumatology [dot] com (jgalindo[at]irisrheumatology[dot]com)
Sarasota
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Jaishree Manohar
Sarasota Arthritis Center
1945 Versailles Street
Sarasota, FL 34239
Contact: Angi Gomez
Phone: +1 941 365 0770
Email: angi [at] arthritiscenters [dot] net (angi[at]arthritiscenters[dot]net)
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Jaishree Manohar
Sarasota Arthritis Center
1945 Versailles St
Suite 101
Sarasota FL 34239
Contact: Katie Decker
Phone: (941)365-0770
Email: katie [at] arthritiscenters [dot] net (katie[at]arthritiscenters[dot]net)
South Miami
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Olga Kromo
BioResearch Partner
6280 Sunset Drive
South Miami, FL 33143
Contact: Dayme Tamarit
Phone: +1 833 489 4968
Email: dtamarit [at] bioresearchpartner [dot] com (dtamarit[at]bioresearchpartner[dot]com)
Tamarac
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)- Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Kevin Stone, MD
West Broward Rheumatology Associates, Inc.
7431 N University Drive
Tamarac, FL 33321
Contact: Rochelle Durfy
Phone: (954) 545-8400
Email: durfywbra [at] gmail [dot] com (durfywbra[at]gmail[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)- Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Kevin Stone, MD
West Broward Rheumatology Associates, Inc.
7431 N University Drive Ste 300
Tamarac, FL 33321-2956
Contact: Jennifer Perez
Phone: (954) 545-8400
Email: jperezwbra [at] gmail [dot] com (jperezwbra[at]gmail[dot]com)
Tampa
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Shanmugapriya Reddy, MD
Clinical Research of West Florida Inc - Tampa
605 N Howard Ave
Tampa, Florida 33606-1246
Contact: Abby Carlson
Phone: (813) 870-1292
Email: acarlson [at] crwf [dot] com (acarlson[at]crwf[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Michael Burnette, MD
BayCare Medical Group Primary Care and Rheumatology - Tampa
4612 N Habana Ave
Tampa, FL 33614-7101
Contact: Tori Norris
Phone: (813) 840-3600
Email: tori [dot] edwards [at] baycare [dot] com (tori[dot]edwards[at]baycare[dot]com)
Augusta
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Elena Schiopu
Augusta University
1120 15th Street
Augusta, GA 30912
Contact: Whitney McDaniel
Phone: (706) 721-2982
Email: whmcdaniel [at] augusta [dot] edu (whmcdaniel[at]augusta[dot]edu)
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Elena Schiopu, MD
Augusta University
1120 15th St
Augusta, GA 30912
Contact: Michelle Collins
Phone: (706) 721-1075
Email: mcollins2 [at] augusta [dot] edu (mcollins2[at]augusta[dot]edu)
Rockford
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Saad Tariq, MD
OrthoIllinois, LTD
5875 E Riverside Blvd
Rockford, IL 61114-4937
Contact: Heather Hackman
Phone: (815) 381-7468
Email: heather [dot] hackman [at] orthoillinois [dot] com (heather[dot]hackman[at]orthoillinois[dot]com)
Skokie
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Robert Hozman
Clinical Investigation Specialists - Clinic of Robert Hozman
4709 West Golf Rd
Skokie, IL 60076
Contact: Iryna Shevchuk
Phone: +1 847 599 2492
Email: ishevchuk [at] cisresearch [dot] com (ishevchuk[at]cisresearch[dot]com)
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Robert Hozman, MD
Clinic of Robert Hozman/Clinical Investigation Specialists Inc.
4709 Golf Road
Skokie, IL 60076
Contact: Megi Stafa
Phone: (847) 599-2492
Email: mstafa [at] cisresearch [dot] com (mstafa[at]cisresearch[dot]com)
Iowa City
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Hanna Zembrzuska
University of Iowa Hospital and Clinics
200 Hawkins Drive
Iowa City, IA 52242
Contact: Ashley Pieper
Phone: +1 319 356 3507
Email: ashley-pieper [at] uiowa [dot] edu (ashley-pieper[at]uiowa[dot]edu)
Kansas City
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Ghaith Noaiseh, MD
University of Kansas Medical Center
3901 Rainbow Boulevard
Kansas City, KS 66103
Contact: Jill Case
Phone: (913) 588-0653
Email: Jcase2 [at] kumc [dot] edu (Jcase2[at]kumc[dot]edu)
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Ghaith Noaiseh, MD
University of Kansas Medical Center
3901 Rainbow Blvd.
Kansas City, KS 60160
Contact: Vanessa Verschelden
Phone: (913) 588-0653
Email: vbarrientos [at] kumc [dot] edu (vbarrientos[at]kumc[dot]edu)
Baton Rouge
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Saravanan Thiagarajan, MD
Ochsner Health Center - Baton Rouge
10310 The Grove Blvd.
Baton Rouge, LA 70836
Contact: Ashunti Pearson
Phone: (225) 761-5278
Email: aspearson [at] ochsner [dot] org (aspearson[at]ochsner[dot]org)
Lake Charles
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Enrique Mendez, MD
Accurate Clinical Research - Lake Charles
1727 Imperial Blvd Bldg 1 # STE B
Lake Charles, Louisiana 70605-5393
Contact: Jacob Seep
Phone: (337) 312-8617
Email: jseep [at] accurateclinicalresearch [dot] com (jseep[at]accurateclinicalresearch[dot]com)
Baltimore
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Thomas Grader-Beck, MD, PhD
Johns Hopkins Medicine - Jerome L. Greene Sjögren's Center
5200 Eastern Ave Ste 4100 Rm 413
Baltimore, MD 21224-2746
Contact: Jennifer Reed
Phone: (410) 550-6492
Email: jreed52 [at] jhu [dot] edu (jreed52[at]jhu[dot]edu)
Bethesda
Blake M Warner, D.D.S
National Institute of Dental and Craniofacial Research
NIH Clinical Center - On the Metro red line (Medical Center stop)
Bethesda, Maryland
STUDY # 20-D-0131
Contact: Sasha Clary
Email: sasha [dot] clary [at] nih [dot] gov (sasha[dot]clary[at]nih[dot]gov)
Phone: (301) 529 -7924
Click here to learn more about Study #20-D-0131
En Español
Columbia
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
James Bellor Jr., MD
Kur Research at Columbia Medical
5450 Knoll North Dr Ste 270
Columbia, Maryland 21045-2394
Contact: Brittney Lewis-Weekes
Phone: (410) 964-6115
Email: blewis-weekes [at] kurr [dot] com (blewis-weekes[at]kurr[dot]com)
Boston
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Pedram Hamrah
Tufts Medical Center
800 Washington Street
Boston, MA 02111
Contact: Nancy Gee
Phone: +1 617 636 5489
Email: ngee [at] tuftsmedicalcenter [dot] org (ngee[at]tuftsmedicalcenter[dot]org)
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Athena Papas, DDS, DMD, MD, PhD
Tufts Medical Center - PPDS
1 Kneeland St
Boston, Massachusetts 02111-1527
Contact: Joseph Cimmino
Phone: (617) 636-3931
Email: joseph [dot] cimmino [at] tufts [dot] edu (joseph[dot]cimmino[at]tufts[dot]edu)
Study #00002230
Click here for more information
Dr. Addy Alt-Holland and Dr. Mabi Singh
Tufts University School of Dental Medicine
1 Kneeland Street
Boston, MA 02111
Contact Name: Tiffany Bairos, Lead Coordinator
Phone: (617) 636-2408
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Athena Papas, MD
Tufts Medical Center - Rheumatology Research Office
1 Kneeland Street
Boston, MA 02111
Contact: Joseph Cimmino
Phone: (617) 636-6515
Email: joseph [dot] cimmino [at] tufts [dot] edu (joseph[dot]cimmino[at]tufts[dot]edu)
St. Claire Shores
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Amar Majjhoo, MD
Shores Rheumatology
29200 Harper Ave
St. Clair Shores, MI 48081
Contact: Danielle Dickey
Phone: (586) 777-6841
Email: ddickey [at] researchmi [dot] com (ddickey[at]researchmi[dot]com)
Eagan
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Elvia Moreta
St. Paul Rheumatology P A
2854 Hwy 55 Suite 190
Eagan, MN 55121
Contact: Yolanda Margarita Fabelo
Phone: +1 651 361 8569
Email: margarita [at] sprdrem [dot] com (margarita[at]sprdrem[dot]com)
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
David Ridley, MD
St. Paul Rheumatology
2854 Hwy. 55, Ste. 190
Eagan, MN 55121
Contact: Zsofia Czegledi
Phone: (651) 361-8659
Email: zsofia [at] sprdrem [dot] com
Kansas City
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Tina Shah, MD
Kansas City Physician Partners- 8350 N Saint Clair Ave
8350 N Saint Clair Ave Ste 100
Kansas City, MO 64151-5102
Contact: Micah Judd
Phone: (816) 268-7512
Email: micah [dot] judd [at] azathritis [dot] com (micah[dot]judd[at]azathritis[dot]com)
Summit
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Elliot Rosenstein, MD
Institute for Rheumatic & Autoimmune Diseases, Overlook Medical Center
33 Upper Overlook Rd # 211
Summit, NJ 07901
Contact: Cynthia Ramdass
Phone: (908) 598-7940
Email: cynthia [dot] ramdass [at] atlantichealth [dot] org (cynthia[dot]ramdass[at]atlantichealth[dot]org)
Voorhees
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Ruchika Patel, MD
Arthritis, Rheumatic & Bone Disease Associates
2301 Evesham Road
Voorhees, NJ 08043
Contact: Jessica Reibel
Phone: (856) 424-5005
Email: jreibel [at] arbda [dot] com (jreibel[at]arbda[dot]com)
Albuquerque
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Leroy Pacheco, MD
Albuquergue Center for Rheumatology
711 Encino Place NE
Albuquerque, NM 87102
Contact: Tianna Dunlap
Phone: (505) 224-2710
Email: tdunlap [at] abqrheum [dot] net (tdunlap[at]abqrheum[dot]net)
Brooklyn
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
David Goddard, MD
NYU Langone Health- Joseph S. and Diane H. Steinberg Ambulatory Care Center
186 Joralemon Street, 8th floor
Brooklyn, NY 11201
Contact: Debra London
Phone: (929) 455-2585
Email: studycoordinatorgoddard [at] gmail [dot] com (studycoordinatorgoddard[at]gmail[dot]com)
Mineola
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Steve Carsons, MD
NYU Langone Hospital - Long Island
101 Mineola Blvd
Mineola, NY 11501
Contact: Melissa Allman
Phone: (516) 663-9582
Email: melissa [dot] allman [at] nyulangone [dot] org (melissa[dot]allman[at]nyulangone[dot]org)
New York
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Allen Yuyin Chen
NYU Langone Medical Centre Hospital for Joint Diseases
333 East 38th Street
New York, NY 10016
Contact: Marie Hwang
Phone: +1 425 516 5789
Email: marie [at] overlakearthritis [dot] com (marie[at]overlakearthritis[dot]com)
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Frederick Ast, MD
Pioneer Clinical Research NY
37 E 30th St Ste 1A
New York, New York 10016-7313
Contact: Nilay Mehta
Phone: (321) 578-1144
Email: nmehta [at] pioneerclinicalny [dot] com (nmehta[at]pioneerclinicalny[dot]com)
Charlotte
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Leslie Ranken
Atrium Health SouthPark Rheumatology
4525 Cameron Valley Parkway
Charlotte, NC 28211
Contact: Daxita Patel
Phone: (704) 446-1844
Email: daxita [dot] patel [at] atriumhealth [dot] org (daxita[dot]patel[at]atriumhealth[dot]org)
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Emily Box, MD
DJL Clinical Research PLLC
431 N Wendover Rd
Charlotte, North Carolina 28211-1064
Contact: Jennifer Bryson
Phone: (704) 247-9179
Email: jennifer [dot] bryson [at] djlresearch [dot] com (jennifer[dot]bryson[at]djlresearch[dot]com)
Durham
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Teresa Tarrant, MD
Duke Early Phase Clinical Research Unit
Rm. 010 Baker House
200 Trent Drive
Durham, NC 27710
Contact: Julianna Ethridge
Phone: (919) 681-5871
Email: julianna [dot] ethridge [at] duke [dot] edu (julianna[dot]ethridge[at]duke[dot]edu)
Salisbury
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Rakesh Patel
Onsite Clinical Solutions
1809 Brenner Avenue
Salisbury, NC 28144
Contact: Diana Tassone
Phone: +1 800 785 3150
Email: dtassone [at] onsiteclinical [dot] com (dtassone[at]onsiteclinical[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Nilesh Patel, MD
Onsite Clinical Solutions, LLC Salisbury
611 Mocksville Ave.
Salisbury, NC 28144-2705
Contact: Pratiksha Singh
Phone: (800) 785-3150
Email: psingh [at] onsiteclinical [dot] com (psingh[at]onsiteclinical[dot]com)
Oklahoma City
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & JohnsonJohnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Robert Scofield
Oklahoma Medical Research Foundation
825 NE 13th Street
Oklahoma City, OK 73104
Contact: Lena Fuentes
Phone: +1 405 271 7745
Email: lena-fuentes [at] omrf [dot] org (lena-fuentes[at]omrf[dot]org)
Fairborn
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Craig Rohan
Wright State Physicians Health Center
725 University Boulevard
Fairborn, OH 45324
Contact: Jessica Hong
Phone: +1 937 245 7500
Email: jessica [dot] hong [at] wrightstatephysicians [dot] org (jessica[dot]hong[at]wrightstatephysicians[dot]org)
Miamisburg
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Chacko Alappatt, MD
Arthritis & Osteoporosis Center of Southwest Ohio - Miamisburg
2960 Ferndown Dr
Miamisburg, OH 45342-3585
Contact: Megan Heffner
Phone: (513) 420-8195
Email: megan [dot] heffner [at] statresearch [dot] com (megan[dot]heffner[at]statresearch[dot]com)
Toledo
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Bashar Kahaleh, MD
University of Toledo Medical Center
3000 Arlington Avenue
Toledo, OH 43614
Contact: Jennifer Gilmore
Phone: (419) 383-6761
Email: jennifer [dot] gilmore [at] utoledo [dot] edu (jennifer[dot]gilmore[at]utoledo[dot]edu)
Vandalia
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Sanford Wolfe, DO
STAT Research
600 Aviator Ct Ste 100B
Vandalia, OH 45377-9474
Contact: Laura Earle
Phone: (856) 424-5005
Email: laura [dot] earle [at] statresearch [dot] com (laura[dot]earle[at]statresearch[dot]com)
Duncansville
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Alan Kivitz
Altoona Center for Clinical Research
175 Meadowbrook Ln
Duncansville, PA 16635
Contact: Kaylee Campagna
Phone: +1 814 693 0300
Email: kayleecampagna [at] altoonaresearch [dot] com (kayleecampagna[at]altoonaresearch[dot]com)
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Alan Kivitz, MD
Altoona Center for Clinical Research
175 Meadowbrook Ln
Duncansville, PA 16635
Contact: Heather Breon
Phone: (814) 693-0300
Email: heatherbreon [at] altoonaresearch [dot] com
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Alan Kivitz, MD
Altoona Center for Clinical Research
175 Meadowbrook Ln
Duncansville, Pennsylvania 16635-8445
Contact: Lisa Claycomb
Phone: (814) 693-0300
Email: altoonaresearch [at] gmail [dot] com (altoonaresearch[at]gmail[dot]com)
San Juan
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Gregorio Cortes-Maisonet, MD
GCM Medical Group
Urb. Floral Park #62 Calle Jose Marti
San Juan, PR 00917
Contact: Bryan Rivera Otero
Phone: (787) 936-2100 EXT 10
Email: brivera [at] gcmmedical [dot] com (brivera[at]gcmmedical[dot]com)
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Oscar Soto-Raices, MD
Mindful Medical Research
576 Cesar Gonzalez Ave
San Juan, PR 00918
Contact: Franco Alonso
Phone: (787) 765-9034
Email: falonso [at] mmr-pr [dot] com (falonso[at]mmr-pr[dot]com)
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Gregorio Cortes-Maisonet, MD
GCM Medical Group
62 Calle Jose Marti
San Juan, PR 00917
Contact: Luis Martinez Miranda
Phone: (787) 598-5853
Email: lmiranda [at] gcmmedical [dot] com
Jackson
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Jacob Aelion
West Tennessee Research Institute
369 North Parkway, Suite 400
Jackson, TN 38305
Contact: Kim Smith
Phone: (731) 664-0002
Email: ksmith [at] arthritisclinic [dot] org (ksmith[at]arthritisclinic[dot]org)
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Jacob Aelion, MD
West Tennessee Research Institute
369 N Parkway Ste 400
Jackson, Tennessee 38305-2883
Contact: Sherry Wiggins
Phone: (731) 633-0045
Email: swiggins [at] arthritisclinic [dot] org (swiggins[at]arthritisclinic[dot]org)
Murfreesboro
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Marcus Owen, MD
Murfreesboro Medical Clinic- Westlawn
3325 Shores Road
Murfreesboro, TN 37128
Contact: Jennifer Neal
Phone: (212) 427-6656 EXT 627
Email: jennifer [dot] neal [at] azarthritis [dot] com (jennifer[dot]neal[at]azarthritis[dot]com)
Allen
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Megha Patel-Banker, MD
Arthritis & Rheumatology Research Institute, PLLC
981 TX-121 Suite #3150
Allen, TX 75013
Contact: Guadalupe Cindo
Phone: (972) 798-8553
Email: l [dot] cindo [at] dfwarthritis [dot] com
Amarillo
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Constantine Saadeh, MD
Amarillo Center For Clinical Research - ClinEdge
6842 Plum Creek Dr
Amarillo, TX 79124-1601
Contact: Alina Noynouanpheng
Phone: (806) 352-2453
Email: anoynouanpheng [at] allergyarts [dot] com (anoynouanpheng[at]allergyarts[dot]com)
Austin
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Paul Pickrell, MD
Tekton Research, LLC - Austin - PPDS
4534 Westgate Boulevard, Suite 110
Austin, Texas 78745
Contact: John Luna
Phone: (512) 388-5717
Email: jluna [at] tektonresearch [dot] com (jluna[at]tektonresearch[dot]com)
Baytown
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Sabeen Najam, MD
Accurate Clinical Management- Baytown
1610 W Baker Road, Suite C
Baytown, TX 77521
Contact: Mariela Martinez
Phone: (281) 851-7088
Email: mmartinez [at] accurateclinicalresearch [dot] com (mmartinez[at]accurateclinicalresearch[dot]com)
Grapevine
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Uzma Syeda, MD
Precision Comprehensive Clinical Research Solutions
1501 W Northwest Hwy
Grapevine, TX 76051-3143
Contact: Akhil Gangasani
Phone: (972) 299-8399
Email: akhilgangasani [at] pccrsolutions [dot] com (akhilgangasani[at]pccrsolutions[dot]com)
Houston
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Michelle Eisenberg, DO
Prolato Clinical Research Center
11920 Astoria Blvd Ste 200
Houston, Texas 77089-6155
Contact: Romeo Parada
Phone: (832) 338-9118
Email: rparada [at] prolato [dot] org (rparada[at]prolato[dot]org)
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Nada Mustafa, MD
Trio Clinical Trials
1235 North Loop W Ste 220
Houston, Texas 77008-1772
Contact: Zitiali Alanis
Phone: (713) 869-1825
Email: zalanis [at] trioclinical [dot] com (zalanis[at]trioclinical[dot]com)
Katy
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Maryam Khawari, MD
R & H Clinical Research-Katy
777 S Fry Rd Ste 102
Katy, Texas 77450-2297
Contact: Imran Chunawala
Phone: (713) 367-2791
Email: imran [at] rhclinicalresearch [dot] com (imran[at]rhclinicalresearch[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Maryam Khawari, MD
R & H Clinical Research-777 S Fry Rd
777 S Fry Road Ste 102
Katy, TX 77450
Contact: Denise Rodriguez
Phone: (713) 367-2791
Email: denise [at] rhclinicalresearch [dot] com (denise[at]rhclinicalresearch[dot]com)
Katy
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Tara Rizvi, MD
Houston Rheumatology and Arthritis Specialists, PLLC
23920 Katy Fwy Ste 440
Katy, TX 77494-1341
Contact: Ana Gutierrez
Phone: (281) 944-3610
Email: ana [at] biopharmainfo [dot] net (ana[at]biopharmainfo[dot]net)
McAllen
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Elvin Garcia, MD
Valley Arthritis Center
811 E Fern Ave
McAllen, TX 78501
Contact: Clarisa Garza
Phone: (281) 944-3610
Email: cgarza [at] biopharmainfo [dot] net (cgarza[at]biopharmainfo[dot]net)
San Antonio
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Augustin Escalante, MD
University of Texas - San Antonio - Health Science Center
7703 Floyd Curl Drive
San Antonio, TX 78229
Contact: Jose Restrepo
Phone: (210) 567-4656
Email: restreposuar [at] uthscsa [dot] edu (restreposuar[at]uthscsa[dot]edu)
The Woodlands
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Tamar Brionez
Advanced Rheumatology of Houston
10857 Kuykendahl Rd Suite 160
The Woodlands, TX 77382
Contact: Gabriela Obeidat
Phone: +1 936 681 4882
Email: gabby [at] advancedrheum [dot] com (gabby[at]advancedrheum[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Tamar Brionez, MD
Advanced Rheumatology of Houston
10857 Kuykendahl Road Ste 160
The Woodlands, TX 77382
Contact: Elizabeth Soriano
Phone: (936) 681-4882
Email: elizabeth [at] advancedrheum [dot] com (elizabeth[at]advancedrheum[dot]com)
Tomball
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)- Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Shaikh Ali, MD
DM Clinical Research - Tomball - PPDS
13414 Medical Complex Dr Ste 2
Tomball, TX 77375-3333
Contact: Bylinda Vo-Le
Phone: (281) 517-0550
Email: bylinda [dot] vo-le [at] dmclinical [dot] com (bylinda[dot]vo-le[at]dmclinical[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)- Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Shaikh Ali, MD
DM Clinical Research - Migraine and COPD - PPDS
13414 Medical Complex Dr Ste 10
Tomball, TX 77375-3333
Contact: Sahithi Bethelli
Phone: (281) 517-0550
Email: sahithi [dot] bethelli [at] dmclinical [dot] com (sahithi[dot]bethelli[at]dmclinical[dot]com)
Bellevue
DAFFODIL Phase 3 Study
Nipocalimab
Johnson & Johnson
Janssen Research & Development, LLC
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Arinola Dada
Overlake Arthritis and Osteoporosis Center
2100 116th Avenue Northeast Wilburton
Bellevue, WA 98004
Contact: Insiya Nehal
Phone: +1 425 516 5789
Email: inehal [at] overlakearthritis [dot] com (inehal[at]overlakearthritis[dot]com)
Bothell
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Jeff Peterson, MD
Western Washington Medical Group
1909 214th St SE Ste 211
Bothell, WA 98021-4418
Contact: Aubrey Hubble
Phone: (425) 248-2635
Email: ahubble [at] wwmedgroup [dot] com (ahubble[at]wwmedgroup[dot]com)
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Jeff Peterson, MD
Western Washington Medical Group
1909 214th St SE Ste 211
Bothell, WA 98021-4418
Contact: Kavya Rudra
Phone: (425) 248-2635
Email: krudra [at] wwmedgroup [dot] com (krudra[at]wwmedgroup[dot]com)
Seattle
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Kwanghoon Bobby Han, MD
University of Washington Medical Center
1959 NE Pacific Street
Seattle, WA 98195
Contact: Megan Tran
Phone: (206) 616-5330
Email: megant99 [at] medicine [dot] washington [dot] edu
Spokane
Deucravacitinib (IM011-1069) Phase 3
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Michael Coan, DO
Arthritis Northwest
105 W 8th Ave Ste 6080
Spokane, WA 99204
Contact: Jace Cullley
Phone: (509) 838-6500 EXT 119
Email: jculley [at] arthritisnw [dot] com (jculley[at]arthritisnw[dot]com)
Beckley
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Click here to learn more
Wassim Saikali, MD
Rheumatology and Pulmonary Clinic
421 Carriage Dr
Beckley, WV 25801-2805
Contact: Catie Webb
Phone: (304) 256-0245
Email: webb [dot] catie421 [at] gmail [dot] com (webb[dot]catie421[at]gmail[dot]com)
Madison
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Click here to learn more
Sara McCoy, MD
University Of Wisconsin - Madison
600 Highland Avenue
Madison, Wisconsin 53792
Contact: Matt Gilles
Phone: (608) 263-4505
Email: mpgilles [at] clinicaltrials [dot] wisc [dot] edu (mpgilles[at]clinicaltrials[dot]wisc[dot]edu)
Below are additional links that will help you find clinical trials in your area:
The NIH Clinical Research Trials and You website provides general information on participating in clinical research, with a focus on NIH-funded research.
MedlinePlus is a Web-based health information service of the National Library of Medicine.
FDA is responsible for ensuring the safety and effectiveness of drugs, vaccines, and other medical products. Read more about clinical trials and the drug development process on the FDA’s website.
ClinicalTrials.gov is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals. To find trials related to Sjögren's:
Click the link to clinicaltrials.gov
On the LEFT: check the recruiting box to limit to trials actively recruiting THEN click APPLY
On the TOP: click the "on map" tab to see map of US
Click individual states to see available recruiting trials
CenterWatch.com Clinical Trial Listing Service provides patients with unbiased information on clinical trials, with a clinical trial database that contains thousands of currently enrolling trials. Information on drugs and new medical therapies are available to review. CenterWatch also provides patients with health and educational resources about clinical trials and other health information.